Company Overview and News

 
Valeo In A Lull, But Bringing In The Orders

2018-05-22 seekingalpha
Valeo has seen a pronounced slow-down in organic revenue growth, but management is confident that it is a momentary lull as contracts transition.

 
BWA / BorgWarner, Inc. 8-K (Current Report)

2018-05-15 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 
BWA / BorgWarner, Inc. 8-K (Current Report)

2018-05-02 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 
Autoliv (ALV) Q1 Earnings Lag Estimates, Revenues Surpass

2018-04-30 zacks
Autoliv, Inc. (ALV) reported adjusted earnings of $1.66 per share in first-quarter 2018, missing the Zacks Consensus Estimate of $1.81. However, the bottom line improved from the prior-year quarter’s $1.65.

 
BorgWarner (BWA) Q1 2018 Results - Earnings Call Transcript

2018-04-27 seekingalpha
Good morning. My name is Dan, and I'll be your conference facilitator. At this time, I would like to welcome everyone to the BorgWarner 2018 First Quarter Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer period.

 
BWA / BorgWarner, Inc. 10-Q (Quarterly Report)

2018-04-26 sec.gov
Document Table of Contents <

 
BorgWarner (BWA) Q1 Earnings & Revenues Surpass Estimates

2018-04-26 zacks
BorgWarner Inc. (BWA - Free Report) delivered adjusted earnings of $1.10 per share in first-quarter 2018, beating the Zacks Consensus Estimate of $1.03. Adjusted earnings increased from 91 cents per share in the year-ago quarter.

 
BorgWarner (BWA) Q1 Earnings Beat Estimates, Gains Y/Y

2018-04-26 zacks
BorgWarner Inc. (BWA - Free Report) offers efficient and clean technology solutions, essential for combustion, hybrid and electric vehicles. The company reported adjusted earnings of $1.10 per share in first-quarter 2018, beating the Zacks Consensus Estimate of $1.03. Adjusted earnings increased from 91 cents reported in the year-ago quarter.

1
BWA / BorgWarner, Inc. 8-K (Current Report)

2018-04-26 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 
BWA / BorgWarner, Inc. 8-K (Current Report)

2018-04-26 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 
BorgWarner Expects Strong 2018 Growth, Well-Positioned For Global Hybrid And EV Growth

2018-04-25 seekingalpha
Healthy growth is expected from Europe and APAC markets, as well as turbocharger adoption in North America and Asia.

 
Auto Stocks Q1 Earnings: Key Forecasts for GM, BWA and More

2018-04-25 zacks
The first-quarter earnings season is in full swing. A few automakers have already released their earnings while a majority of them will release theirs in the next few days. On Apr 24, PACCAR Inc. (PCAR - Free Report) and Harley-Davidson Inc. (HOG - Free Report) reported first-quarter earnings. Both the companies reported earnings beat for the quarter. Per the latest Earnings Preview, 87 companies from the S&P 500 category have already announced first-quarter results as of Apr 20, registering earnings and revenue beat ratios of 82.

 
Honda (HMC) to Release Q4 Earnings: What's in the Cards?

2018-04-25 zacks
Honda Motor Company (HMC - Free Report) is expected to report fourth-quarter fiscal 2018 (ended Mar 31, 2018) results on Apr 27. Last quarter, the company delivered a positive surprise of 42.3%. In fact, Honda surpassed expectations in each of the trailing four quarters with an average beat of 66.7%. Honda has expected long-term growth rate of 4.8%. In the last six months, shares of Honda have outperformed the industry it belongs to.

 
Harley-Davidson (HOG) Q1 Earnings Beat Estimates, Falls Y/Y

2018-04-24 zacks
Harley-Davidson, Inc. (HOG - Free Report) reported adjusted earnings of $1.03 per share in first-quarter 2018, beating the Zacks Consensus Estimate of 89 cents. Adjusted earnings in the year-ago quarter were $1.05.

 
Will Progress in Production Aid Tesla's (TSLA) Q1 Earnings?

2018-04-24 zacks
Tesla, Inc. (TSLA - Free Report) is expected to report first-quarter earnings results on May 2, after the market closes. Last quarter, the electric carmaker delivered an earnings beat of 4.7%. In the trailing four quarters, the company missed estimates twice and beat on the other two, with an average negative earnings surprise of 31.2%. Let us see, how things are shaping up for this announcement.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

22h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 099724106